4
Indication details
- Control Arm
- Gefitinib or erlotinib
- Therapeutic Indication
- Previously untreated EGFR mutated (exon 19 deletion or L858R)
- Tumour Type
-
Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour Stage
- Advanced
- Tumour Sub-Group
- EGFR+ (exon 19 deletion or L858R)
- Trial Name
- FLAURA
- NCT Number
- NCT02296125
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approved
- EMA Approval
- EMA (CHMP) April 2021 EC decision June 2021
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Evaluated Outcome
- PFS
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 10.2 months
- PFS Gain
- 8.7 months
- PFS HR
- 0.46 (0.37-0.57)
- OS Control
- 31.8 months
- OS Gain
- 6.8 months
- OS HR
- 0.80 (0.64-1.00)
Adjustments
- QoL Comment
-
QoL similar between arms
- Toxicity Comment
-
Improved toxicity profile
Score (after adjustments)
- Preliminary non-curative score
-
3
- Toxicity adjustment
- 1+
- Non-curative score
-
4
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 123
- Scorecard version
- 1
- Issue date
- 15.05.2019
- Last update
- 17.08.2023
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.